Your browser doesn't support javascript.
loading
Association of testosterone therapy with disease progression in older males with COVID-19.
Baillargeon, Jacques; Kuo, Yong-Fang; Westra, Jordan; Lopez, David S; Urban, Randall J; Williams, Stephen B; Raji, Mukaila A.
Afiliação
  • Baillargeon J; Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
  • Kuo YF; Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
  • Westra J; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
  • Lopez DS; Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
  • Urban RJ; Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
  • Williams SB; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
  • Raji MA; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
Andrology ; 10(6): 1057-1066, 2022 09.
Article em En | MEDLINE | ID: mdl-35486968
IMPORTANCE: Low testosterone levels in males have been linked with increase in proinflammatory cytokines-a primary culprit in COVID-19 disease progression-and with adverse COVID-19 outcomes. To date, however, no published studies have assessed the effect of testosterone therapy on COVID-19 outcomes in older men. OBJECTIVE: To examine whether testosterone therapy reduced disease progression in older men diagnosed with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Nested within a national cohort of older (aged ≥50 years) male patients diagnosed with COVID-19 between January 1, 2020 and July 1, 2021 from the Optum electronic health record COVID-19 database, two matched case-control studies of COVID-19 outcomes were conducted. Cases-defined, respectively, as persons who (a) were hospitalized ≤30 days after COVID-19 diagnosis (n = 33,380), and (b) were admitted to the intensive care unit or received mechanical ventilation during their COVID-19 hospitalization (n = 10,273)-were matched 1:1 with controls based on demographic and clinical factors. EXPOSURES: Testosterone therapy was defined based on receipt of prescription at ≤60, ≤90, or ≤120 days before COVID-19 diagnosis. MAIN OUTCOMES AND MEASURES: Adjusted odds ratios (ORs) for the risk of hospitalization within 30 days of COVID-19 diagnosis and intensive care unit admission/mechanical ventilation during COVID-19 hospitalization. RESULTS: The use of testosterone therapy was not associated with decreased odds of hospitalization (≤60 days: OR = 0.92, 95% confidence interval [CI] = 0.70-1.20; ≤90 days: OR = 0.87, 95% CI = 0.68-1.13; ≤120 days: OR = 0.97, 95% CI = 0.72-1.32) or intensive care unit admission/mechanical ventilation (≤60 days: OR = 0.67, 95% CI = 0.37-1.23; ≤90 days: OR = 0.63, 95% CI = 0.36-0.11; ≤120 days: OR = 0.58, 95% CI = 0.29-1.19). CONCLUSIONS AND RELEVANCE: This study showed that testosterone therapy was not associated with decreased risks of COVID-19 adverse outcomes. These findings may provide clinically relevant information regarding testosterone treatment in older men with COVID-19 and other respiratory viral infections with similar pathogenesis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: Andrology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: Andrology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos